400 million adults are obese. These numbers are projected to rise exponentially; more than 700 million are expected to be obese by 2015, and the number of people with diabetes is expected to double by 2030. Many laboratories worldwide have dedicated major efforts to elucidate the mechanisms responsible for the development of these metabolic disorders, with particular emphasis on the mechanistic regulation of energy and nutrient homeostasis. To unveil the pathways that regulate both energy and nutrient homeostasis, the central nervous system (CNS), or more specifically the hypothalamus, has received much attention recently. The hypothalamus detects a rise in nutrients or fat/gut-derived hormones to regulate both energy (7, 9 -11, 19, 21, 23, 24, 28, 35) and nutrient (2, 3, 5, 8, 12, 14, 15, 17, 18, 25, 27, 28, 30, 31) homeostasis. Importantly, obesity and diabetes are associated with disruptions in hypothalamic sensing mechanisms, leading to an elevation of food intake (FI), body weight (BW), and glucose levels (12, 13, 17, 33, 34) . Thus the dissection of CNS sensing mechanisms that regulate energy and nutrient homeostasis in normal and pathological settings is critical and could eventually be proven useful in treating obesity and type 2 diabetes mellitus.
central nervous system; obesity; diabetes THE INCIDENCE OF OBESITY and type 2 diabetes mellitus has reached epidemic proportion. It is estimated that more than 180 million people worldwide have diabetes and approximately 400 million adults are obese. These numbers are projected to rise exponentially; more than 700 million are expected to be obese by 2015, and the number of people with diabetes is expected to double by 2030. Many laboratories worldwide have dedicated major efforts to elucidate the mechanisms responsible for the development of these metabolic disorders, with particular emphasis on the mechanistic regulation of energy and nutrient homeostasis. To unveil the pathways that regulate both energy and nutrient homeostasis, the central nervous system (CNS), or more specifically the hypothalamus, has received much attention recently. The hypothalamus detects a rise in nutrients or fat/gut-derived hormones to regulate both energy (7, 9 -11, 19, 21, 23, 24, 28, 35) and nutrient (2, 3, 5, 8, 12, 14, 15, 17, 18, 25, 27, 28, 30, 31) homeostasis. Importantly, obesity and diabetes are associated with disruptions in hypothalamic sensing mechanisms, leading to an elevation of food intake (FI), body weight (BW), and glucose levels (12, 13, 17, 33, 34) . Thus the dissection of CNS sensing mechanisms that regulate energy and nutrient homeostasis in normal and pathological settings is critical and could eventually be proven useful in treating obesity and type 2 diabetes mellitus.
Nutrients such as fatty acids, amino acids, and glucose signal the hypothalamus to regulate energy balance (9, 11, 24, 29) . The underlying mechanisms of CNS nutrient sensing have been evaluated (4, 9, 21, 23, 28, 29, 38) , but the associated regulatory mechanisms remain largely unknown. Neuronal uptake of lactate provides fuel for neurons (22) . Furthermore, hypothalamic lactate metabolism has been shown to regulate peripheral glucose and lipid homeostasis in vivo (17, 18) . On the basis of these independent yet parallel findings, we postulated that CNS lactate metabolism regulates energy homeostasis.
We first tested whether a selective increase in central lactate levels regulates FI and BW (Fig. 1A) . We then inhibited central lactate metabolism to pyruvate with the pharmacological lactate dehydrogenase inhibitor oxamate to examine the role of lactate metabolism in the regulation of energy balance (Fig.  1A) . We next increased central pyruvate levels to examine whether pyruvate could recapitulate the effects of central lactate (Fig. 1A ). Finally, we tested whether a selective rise in circulating lactate levels regulates FI and BW, and whether such regulation is mediated through central lactate metabolism to pyruvate (see Fig. 4A 
METHODS

Animal Preparation
Eight-week-old male Sprague-Dawley (SD) rats weighing between 260 and 280 g (Charles River Laboratories, Montreal, QC, Canada) were used for our studies. Rats were housed in individual cages and maintained on a standard light-dark cycle with access to standard rat chow and water ad libitum. Rats were stereotaxically (David Kopf Instruments, Tujunga, CA) implanted with indwelling intracerebroventricular single catheters (2.5 mm posterior of bregma, 0.0 mm lateral from midline, 8.0 mm below skull surface) as previously described (5) . Animals receiving systemic circulating lactate then underwent intravenous catheterization, 5 days after stereotaxic surgery. Recovery from surgery was monitored by measuring daily FI and BW to ensure that animals had stable baseline FI and BW before in vivo experiments were performed. All study protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the University Health Network.
Feeding Protocol
Intracerebroventricular administration. Five days after intracerebroventricular surgery, animals whose daily FI and BW had recovered back to baseline and had been stable for a minimum of three consecutive days underwent the feeding protocol. Baseline measurements of FI and BW were taken on day 0 (10 AM, time Ϫ6 h). Water and food were then withdrawn from the animals. Animals received treatments 1 h before the dark cycle (time 0 h). Animals were injected intracerebroventricularly with 3 l of the following substances over a period of 30 s:
4) oxamate (50 mM), 5) oxamate (50 mM) ϩ L-lactate (5 mM), and 6) pyruvate (5 mM). D-Lactate is a nonactive isoform of L-lactate. The concentration of the various intracerebroventricular treatments is based on previous studies indicating that CNS lactate metabolism regulates glucose and lipid production (17, 18) . A dose-response curve for the effects of intracerebroventricular lactate (0.5, 1, and 2.5 mM) injections was also performed. Water and standard chow were given back to the animals at the onset of the dark cycle. FI and BW were monitored at 10 AM for the subsequent 2 days (time 18 h, 42 h).
Intracerebroventricular and intravenous administration. Seven days after intravenous surgery, animals whose daily FI and BW had recovered back to baseline and had been stable for a minimum of three consecutive days underwent the feeding protocol. Baseline measurements of FI and BW were taken on day 0 (10 AM, time Ϫ6 h). Water and food were then withdrawn. At 4 h before the dark cycle (time Ϫ3 h), animals received an intracerebroventricular bolus of oxamate (50 mM; 5 l in 1 min) over 1 min. After the bolus, animals began to receive 3 h of continuous intracerebroventricular administration of oxamate at a rate of 5 l/h and intravenous administration of lactate at a rate of 100 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 . This continuous infusion ended 1 h before the onset of the dark cycle (time 0 h). At the end of the 3 h, animals received an additional intracerebroventricular bolus of oxamate (5 l in 1 min). Water and standard rat chow were given back to the animals at the onset of the dark cycle. FI and BW were monitored at 10 AM for the subsequent 2 days (time 18 h, 42 h).
Calculations
Statistical analysis was done by unpaired Student's t-test or ANOVA where appropriate. Significance was accepted as P Ͻ 0.05. Data are presented as means Ϯ SE.
RESULTS
Central Administration of Lactate Lowers Food Intake and Body Weight
We first subjected male SD rats to intracerebroventricular surgeries and allowed them 1 wk of recovery (Fig. 1B) . Recovered rats only underwent intracerebroventricular injections if their baseline FI (ϳ26 -30 g/day) and BW (ϳ260 -280 g) were stable for a minimum of 3 days. To develop the protocol for FI and BW monitoring in response to a single bolus intracerebroventricular injection, we first injected intracerebroventricular saline (3 l over 30 s) in rats 1 h before the dark cycle (6 h after the initial FI and BW measurements at 10 AM) and monitored their FI and BW for two subsequent days (Fig. 1B) . We found that intracerebroventricular saline injections had minimal effects on FI and BW at 18 (1 day) or 42 (2 days) h (Fig. 1, C and D) . Similarly, intracerebroventricular D-lactate (5 mM; nonactive isoform of lactate) injections had minimal effects on FI and BW (Fig. 1, C and D) . In contrast, intracerebroventricular injections of equivolumes of 5 mM L-lactate 1 h before the dark cycle reduced FI from 29 Ϯ 1 to 12 Ϯ 3 g (a 58 Ϯ 9% decrease) at 18 h (Fig. 1C) . FI was not significantly different after 42 h of intracerebroventricular lactate injections (Fig. 1C) . This is consistent with previous studies indicating that a single bolus intracerebroventricular injection of another nutrient, L-leucine, reduces FI up to 24 h (9), but in contrast to the ability of intracerebroventricular oleic acid to lower FI up to 48 h (29) . Intracerebroventricular lactate reduced BW by 28 Ϯ 5 g (or 10 Ϯ 2%) after 18 h (Fig.  1D) . BW remained significantly lower 42 h after intracerebroventricular lactate injections (Fig. 1D) . Thus we report for the first time, to our knowledge, that a selective rise in central lactate levels reduced FI, which was accompanied by weight loss.
We next performed a dose-response curve for the anorectic effect of a single bolus intracerebroventricular L-lactate injection. We found that intracerebroventricular L-lactate injected at both 0.5 mM and 1 mM had minimal effects on FI and BW at 18 or 42 h (Fig. 1, E and F) . Intracerebroventricular L-lactate injected at 2.5 mM lowered FI from 28 Ϯ 0.9 to 22 Ϯ 1.5 g (P Ͻ 0.05) at 18 h, and FI returned to baseline at 42 h (Fig. 1E) . Intracerebroventricular L-lactate injected at 2.5 mM did not significantly affect BW at 18 h (Fig. 1F) . To further characterize the underlying mechanisms of CNS lactate sensing, we decided to focus on using intracerebroventricular L-lactate injected as a single bolus at 5 mM. This is because the anorectic effect of L-lactate at 5 mM was strongest in accordance with the dose-response curve and this will ensure a relatively maximal stimulation on the downstream biochemical/signaling pathway(s) of CNS lactate sensing.
Central Lactate Metabolism Mediates Lactate to Lower Food Intake and Body Weight
Neuronal lactate serves as an important energy source for neurons (22) . Furthermore, activation of hypothalamic lactate metabolism regulates peripheral glucose and lipid homeostasis (17, 18) . To examine whether central lactate metabolism mediates central lactate in the regulation of energy balance, we first injected the lactate dehydrogenase competitive inhibitor oxamate intracerebroventricularly to inhibit central lactate metabolism to pyruvate (Figs. 1A, 2A ). Central injections of oxamate (50 mM) alone did not affect FI and BW up to 42 h (Fig. 2, B and C) . In contrast, intracerebroventricular oxamate coinjected with L-lactate completely abolished the 18-h effect of central lactate on FI (Fig. 2B) , as well as both the 18-and 42-h effects on BW (Fig. 2C) . These data indicate that central lactate metabolism to pyruvate is required for lactate to regulate FI and BW.
Central Administration of Pyruvate Lowers Food Intake and Body Weight
If central lactate metabolism to pyruvate represents an important biochemical pathway to lower FI and BW, direct intracerebroventricular pyruvate injections should recapitulate the anorectic effects of central lactate. Indeed, intracerebroventricular pyruvate (5 mM; 1 molecule of lactate generates 1 molecule of pyruvate) injections lowered FI from 27 Ϯ 2 to 12 Ϯ 4 g (Fig. 3A) , with an accompanying 18-h BW reduction of 6 Ϯ 2% (Fig. 3B) . The anorectic effects of intracerebroventricular pyruvate closely resemble those observed with intracerebroventricular lactate injections. Together, these data suggested that hypothalamic lactate 3 pyruvate metabolism regulates FI and BW. 
Central Lactate Metabolism Is Required for Circulating Lactate to Lower Food Intake and Body Weight
Direct sensing of glucose (11), fatty acids (29) , amino acids (9) , and lactate (demonstrated in this study) by the brain regulates FI and BW. However, it is unclear whether these CNS nutrient-sensing mechanism(s) mediate circulating nutrients to regulate FI and BW. We here tested whether a selective and sustained doubling of plasma lactate levels for 3 h regulates FI and BW, and whether the associated effects are dependent on CNS lactate metabolism (Fig. 4A) . We subjected rats to intracerebroventricular surgeries on day Ϫ12 and then intravascular surgeries on day Ϫ7. FI and BW returned to baseline by day Ϫ3. After consistent baseline readings for both FI and BW for three extra days, we performed in vivo infusion experiments on day 0 (Fig. 4B) . Intravenous lactate (100 mol⅐kg Ϫ1 ⅐min
Ϫ1
) was infused for 3 h to increase plasma lactate levels from 0.9 Ϯ 0.1 mM (n ϭ 5, iv saline) to 2.1 Ϯ 0.4 mM (n ϭ 6, iv lactate), in keeping with previous studies (17) . Infusion was terminated 1 h before the dark cycle (Fig.  4B) . Intravenous lactate infusion reduced FI from 27 Ϯ 2 to 1 Ϯ 0.5 g (a 98 Ϯ 2% decrease) at 18 h, and FI returned to baseline after 42 h (Fig. 4C) . In parallel, intravenous lactate significantly reduced BW by 43 Ϯ 6 g (or 15 Ϯ 3%) at 18 h, which returned to baseline by 42 h (Fig. 4D) .
In a second set of rats, intracerebroventricular oxamate was injected to inhibit central lactate metabolism to pyruvate in the presence of intravenous lactate infusion (Fig. 4, A and B) . Rats that received central oxamate administration in addition to intravenous lactate only reduced FI from 28 Ϯ 3 to 18 Ϯ 2 g (a 35 Ϯ 7% decrease) after 18 h, returning to slightly higher than baseline after 42 h (Fig. 4C) . BW was unchanged (Fig.  4D) . Of note, central administration of oxamate did not fully abolish the anorectic effects of circulating lactate (Fig. 4C) , indicating that other regions of the brain or other parts of the body could be involved in this appetite regulation. Thus we have demonstrated that central lactate metabolism to pyruvate is required for circulating lactate to regulate FI and BW.
DISCUSSION
The hypothalamus senses nutrients or hormones to exert physiological responses and maintain energy (7, 9 -11, 19, 21, 23, 24, 28, 35) and nutrient (2, 3, 5, 8, 12, 14, 15, 17, 18, 27, 28, 30, 31) homeostasis. The associated hypothalamic mechanisms are potentially disrupted in obesity and diabetes, leading to an elevation of appetite and plasma metabolite level (12, 13, 17, 33, 34) . Although neuronal networks have been demonstrated to regulate energy and nutrient homeostasis, much work is needed to probe the CNS biochemical and signaling path- Fig. 4 . Central administration of oxamate blocks the anorectic effect of circulating lactate. A: schematic model for FI and BW regulation on icv oxamate coadministered with iv lactate. B: icv 3rd ventricle surgery was performed on male SD rats, and they were given 5 days of recovery before iv surgery. Rats were given 7 days for FI and BW to stabilize before feeding protocol. Baseline FI and BW were measured (time Ϫ6 h). Rats were administered icv saline or oxamate (50 mM at 5 l/h) together with iv lactate (100 mol ⅐ kg Ϫ1 ⅐ min
Ϫ1
) for 3 h, ending 1 h before the onset of the dark cycle (time Ϫ4 h to Ϫ1 h); icv bolus of saline or oxamate (50 mM) was given over a 1-min period at the beginning and end of the 3-h continuous infusion. FI and BW were monitored for 2 subsequent days. C and D: effect of icv saline with iv lactate (n ϭ 6) and icv oxamate with iv lactate (n ϭ 5) on FI (C) and %change in BW (D). ‡P Ͻ 0.001, icv saline with iv lactate vs. icv oxamate with iv lactate.
ways that are responsible for these regulations. Research with these particular focuses will reveal new molecular targets to lower FI and plasma metabolite level in obesity and type 2 diabetes mellitus.
The present study extends the quest to uncover novel CNS biochemical pathways and molecules in the regulation of energy homeostasis. We here provide the first direct evidence, to our knowledge, that activation of central lactate metabolism to pyruvate with two independent intracerebroventricular or intravenous lactate-infused approaches reduced FI and BW. This is further supported by the fact that direct central delivery of pyruvate fully recapitulated the anorectic effect of lactate. These studies position the biochemical metabolism of lactate to pyruvate in the hypothalamus as a novel biochemical target to reverse obesity.
Intravenous administration or peripheral injections of nutrients such as lactate, glucose, lipids, or amino acids negatively regulate FI and BW (20, 26, 36, 37, 39) . However, the site(s) of the anorectic actions have not been investigated. Here we report that central lactate metabolism to pyruvate is required for circulating lactate to lower BW and FI in conscious, unrestrained rodents. We first established an in vivo model that illustrated that systemic elevation of plasma lactate levels by ϳ2.5-fold for 3 h lowered FI and BW. In the presence of this systemic elevation of lactate, we then negated central lactate metabolism to pyruvate with central injections of the lactate dehydrogenase inhibitor oxamate at the same dose that abolished the anorectic effects of central lactate injections. Central administrations of oxamate were sufficient to reverse the anorectic effects of circulating lactate. These data suggest that, similar to the regulation of glucose and lipid homeostasis (17, 18) , CNS lactate metabolism is required for circulating lactate to regulate energy homeostasis.
The present study as a whole is pharmacological in nature and is designed to evaluate the role of the biochemical metabolism of lactate to pyruvate in the regulation of FI. The physiological relevance of CNS lactate metabolism to the regulation of FI remains to be clarified. Furthermore, the study does not distinguish the types of neurons [i.e., the agoutirelated peptide (AgRP)/neuropeptide Y (NPY) and proopiomelanocortin (POMC) neurons] that are involved in CNS lactate metabolism. Genetic approaches that target selective populations of neurons and manipulate associated molecules involved in neuronal lactate sensing could be important tools to achieve this goal. In fact, emerging studies are showing that genetic disruptions of CNS nutrient and hormonal sensing mechanisms in AgRP or POMC neurons impair energy and glucose homeostasis (1, 6, 15, 16, 31, 32) .
In conclusion, our data suggest that activation of central lactate metabolism to pyruvate lowers FI and BW. In light of the fact that CNS lactate metabolism controls plasma glucose and lipid levels (17, 18) , therapeutic strategy designed to modulate CNS lactate metabolism may prove useful to lower BW and glucose and lipid levels in obesity and type 2 diabetes mellitus.
